AUPH (Aurinia Pharmaceuticals) Total Equity: $567.6 Mil (As of Mar. 2026)


AUPH Aurinia Pharmaceuticals Inc AUPH
82 GF Score
Price $15.79
GF Value $14.00
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Total Equity?

Aurinia Pharmaceuticals AUPH -6.87% 82 Total Equity is $567.6 Mil as of Mar. 2026. GuruFocus rates AUPH with a GF Score™ of 82/100 and a GF Value™ of $14.00 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Aurinia Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $567.6 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Aurinia Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Total Equity Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 479.09 405.44 377.95 377.48 581.33

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 350.19 335.30 365.77 581.33 567.63
AUPH
82GF Score
Aurinia Pharmaceuticals Inc AUPH
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Aurinia Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=751.587-170.256
=581.3

Aurinia Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=723.997-156.371
=567.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $567.6 Mil mean?
Aurinia Pharmaceuticals (AUPH) has a Total Equity of $567.6 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Total Equity too high?
Aurinia Pharmaceuticals' current Total Equity is $567.6 Mil. Overall, Aurinia Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Total Equity compare to KOD and ABCL?
Aurinia Pharmaceuticals' Total Equity of $567.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Total Equity is $567.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.00, compared to a current price of $15.79 — trading 12.8% above its estimated fair value. The current Total Equity is $567.6 Mil. Aurinia Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Total Equity is $567.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $15.79 is trading 12.8% above its estimated GF Value™ of $14.00. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

  • Total Equity: $567.6 Mil
  • GF Value™: $14.00 vs. price of $15.79 (12.8% above fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges IKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
82GF Score

Get the complete analysis for AUPH

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.79
Price
$14.00
GF Value